NYSE:ZTS
NYSE:ZTSPharmaceuticals

A Look At Zoetis (ZTS) Valuation As Softer Sales Projections Stir Debate Before Q4 2025 Earnings

Zoetis (ZTS) heads into its upcoming Q4 2025 earnings release with investor attention fixed on softer sales projections for certain pet and livestock medicines and debate around a key arthritis drug’s recent performance. See our latest analysis for Zoetis. Zoetis shares currently trade at US$124.65. The recent 90 day share price return of a 13.47% decline and 1 year total shareholder return of a 23.86% decline suggest momentum has been fading as investors reassess growth expectations and risk...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Recent Share Price Weakness

If you are wondering whether Recursion Pharmaceuticals' current share price gives you enough value for the risk you are taking, you are not alone. The stock closed at US$4.67, with returns of 0.2% over the last 7 days, a 0.2% decline over 30 days, an 11.2% gain year to date, and a 28.5% decline over the past year, which can change how investors think about both potential and risk. Recent attention on Recursion has focused on its position within the pharmaceuticals and biotech space and how...